Iressa To The Rescue: Oncology Stocks Stand Out On Wall Street
Executive Summary
Millennium's multiple myeloma agent Velcade is leading the parade of oncologic therapies attracting renewed enthusiasms from investors
You may also be interested in...
Ranexa Run-Up Shows Breadth Of Biotech Rally On Wall Street
CV Therapeutics is a quiet beneficiary of the FDA advisory committee decision regarding the risk of QT prolongation with GSK/Bayer's erectile dysfunction agent Levitra and Sanofi's benign prostatic hyperplasia treatment UroXatral
Ranexa Run-Up Shows Breadth Of Biotech Rally On Wall Street
CV Therapeutics is a quiet beneficiary of the FDA advisory committee decision regarding the risk of QT prolongation with GSK/Bayer's erectile dysfunction agent Levitra and Sanofi's benign prostatic hyperplasia treatment UroXatral
GSK/Corixa Bexxar User Fee Deadline Extended To Review Safety Database
FDA is extending GSK/Corixa's Bexxar user fee deadline by three months to review additional safety information on the radioimmunotherapy